Cancer Immunotherapy Consortium 2012 Scientific Colloquium

National Harbor, Maryland

Day 1, Thursday, April 19, 2012

7:00 am Registration and Continental Breakfast

8:00 am Opening Remarks

Axel Hoos, GlaxoSmithKline, Collegeville, PA

8:30 am Keynote Address
Wolf Fridman
, Centre de Recherche des Cordeliers, Paris, France
The immune microenvironment of primary and metastatic human tumors:
soil or seed?

Session 1: Host Reactions in the Tumor

9:15 am Pierpaolo Correale
, Siena University Hospital, Siena, Italy

9:45 am Padmanee Sharma, The University of Texas MD Anderson Cancer
Center, Houston, TX
Immune monitoring on pre-surgical clinical trials with ipilimumab

10:15 am Weiping Zou, University of Michigan School of Medicine,
Ann Arbor, MI

Human Th17 cells have stem cell feature and mediate long-term anti-tumor

10:45 am Refreshment Break

11:15 am Jerome Galon, Centre de Recherche des Cordeliers, Paris,
The immunoscore: A novel approach for the classification of cancer in
the era of immunotherapies

11:45 am Zaima Mazorra Herrera, Center of Molecular Immunology, Havana,
Two promising vaccines for NSCLC patients: Antibody response as
immunological surrogate of clinical benefit

Session 2: Advances in Imaging

2:00 pm Dirk Jäger, University Hospital Heidelberg, Heidelberg, Germany
Prognostic and predictive significance of the immunological tumor

2:30 pm Michael Dustin, NYU Langone Medical Center, New York, NY
Synergy of radiation-induced NKG2D ligands and anti-CTLA-4 promotes
T cell-mediated elimination of a
poorly immunogenic tumor

3:00 pm Steven Larson, Memorial Sloan-Kettering Cancer Center, New
York, NY
Quantitative PET imaging for the development of antibodies as drugs
3:30 pm Refreshment Break

4:00 pm Glenn Liu, University of Wisconsin Carbone Cancer Center,
Madison, WI
Integrating imaging in early drug development

4:30 pm Philip Murphy, GlaxoSmithKline, Uxbridge, United Kingdom
Quantitative functional tumor imaging

5:00 pm Peter Friedl, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Intravital multiphoton imaging of cancer progression and therapy

7:00 pm Colloquium Dinner

Day 2, Friday, April 20, 2012

Session 3: Monitoring Therapeutic Immune Modulation

8:30 am George Coukos, University of Pennsylvania, Philadelphia, PA

9:00 am Lisa Coussens, Oregon Health & Science University, Portland, OR
Reprogramming immune microenvironments in solid tumors to enhance

9:30 am Daniel Speiser
, University Hospital Lausanne, Lausanne, Switzerland
Ups and downs of small antigenic peptides for CD8 T cell vaccination
against cancer

10:00 am Carl June, University of Pennsylvania, Philadelphia, PA

10:30 am Refreshment Break

11:00 am Thomas Gajewski, University of Chicago, Chicago, IL Lessons learned from the tumor microenvironment to guide advancement in cancer immunotherapy

11:30 am Henry Hepburne-Scott, Serametrix Corporation Serum profiling and immune monitoring for predicting clinical outcomes to immunotherapy

12:00 pm Carlos Santos, Biovest International, Inc.

Autologous vaccine’s tumor-matching isotype correlates with survival benefit for BiovaxID® active immunotherapy for non-Hodgkin's lymphoma

12:30 pm Jedd Wolchok, Memorial Sloan-Kettering Cancer Center, New York, NY Biomarkers of CTLA-4 blockade

1:00 pm Lunch

Session 4: Benefit / Risk of Immunotherapy

2:00 pm Philip Kantoff, Dana-Farber Cancer Institute, Boston, MA
Update on immunotherapy for prostate cancer

2:30 pm Larry Norton, Memorial Sloan-Kettering Cancer Center, New York, NY Cryoablation plus anti-CTLA 4 treatment as an approach to primary breast
cancer: Optimizing benefit/risk of immunotherapy

3:00 pm Vincent Brichard
, GlaxoSmithKline Biologicals, Brussels, Belgium
Development of specific immunotherapty against cancer: Taking benefit
from the host spontaneous response against the tumor

3:30 pm Refreshment Break

4:00 pm Interdisciplinary Roundtable Discussion

The roundtable discussion will address benefit vs. risk in the development of
immunotherapies. The session will be moderated by Jill O’Donnell-Tormey,
Cancer Research Institute and Axel Hoos, GlaxoSmithKline.

Networking Reception

Day 3, Saturday, April 21, 2012

Session 5: CIC Immune Monitoring Program

Moderated by Sylvia Janetzki, ZellNet Consulting

8:00 am Michael Kalos, University of Pennsylvania School of Medicine,
Philadelphia, PA
Results of the Luminex panel

8:30 am Lisa McNeil, Pfizer Inc., Pearl River, NY Harmonization strategies for flow cytometry - results of collaborative ICS gating panel efforts

9:00 am Sebastian Attig, University of Mainz, Mainz, Germany The Multimer panels - recent results and completion of the assay harmonization process

9:30 am Sylvia Janetzki, ZellNet Consulting, Fort Lee, NJ Finalizing MIATA and the harmonization process for ELISPOT performance; and the road ahead

10:00 am Refreshment Break

10:30am Cedrik Britten, Center for Translational Oncology at the University Medical Center (TRON), Mainz, Germany Generation of Reference Samples for T-cell Assays

11:00 am Cecile Gouttefangeas, University of Tuebingen, Tuebingen, Germany Harmonizing immune monitoring T-cell assays, from cell samples to data analysis: Recent proficiency panels of the CIMT Immunoguiding Program 11:30 am Concluding Remarks Axel Hoos, GlaxoSmithKline, Collegeville, PA

Contact Information

Payment Instructions

  • The Early Registration Deadline is Wednesday, March 21, 2012. Registration rates will increase after this date.

    All major credit cards are accepted. If you are paying by check, please make checks payable to Cancer Research Institute. (U.S. funds drawn on U.S. banks only.) Mail a copy of your registration information with your check to:

    2012 CIC Colloquium
    Cancer Research Institute
    One Exchange Plaza
    55 Broadway, Suite 1802
    New York, NY 10006

    Requests for refunds must be submitted in writing by
    Friday, March 16, 2012 to Refund requests received after that date will not be honored. There will be a $100 processing fee for all refunds. Registrations are non-transferable.
© 2018
Quick, easy and affordable online event registration and event management software for all event sizes.